CNSP Share Price | CNS Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is CNS Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, CNS Pharmaceuticals, Inc. has a market capitalization of 4.53 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, CNS Pharmaceuticals reported net sales of 0.00 million and a net profit of -15.62 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.18 million and total assets of 8.70 million.

Q: What does CNS Pharmaceuticals, Inc. do?

Overview: CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors, specifically its lead drug candidate, Berubicin, for glioblastoma. The company operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap with a market cap of USD 4.53 million.Financial Snapshot: Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 4.53 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.17 Return on Equity: -135.44% Price to Book: 0.41Contact Details: Address: 2100 West Loop S Ste 900, HOUSTON TX: 77027-3522 Website: https://cnspharma.com/

Q: Is CNS Pharmaceuticals, Inc. technically bullish or bearish?

As of 1 May 2025, the technical trend for CNS Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI indicates a bullish monthly signal but no signal on the weekly. Bollinger Bands and moving averages are both mildly bearish on the weekly and daily time frames, respectively. Dow Theory presents a mildly bullish weekly view but is bearish on the monthly. In terms of performance, the stock has significantly underperformed against the S&P 500 over the longer term, with a year-to-date return of -87.79% compared to the S&P 500's 12.22%, and a one-year return of -90.81% against the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

37.21 k

Shareholding (Sep 2025)

FII

1.80%

Held by 5 FIIs

DII

97.69%

Held by 1 DIIs

Promoter

0.00%

How big is CNS Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, CNS Pharmaceuticals, Inc. has a market capitalization of 4.53 million, with net sales of 0.00 million and a net profit of -15.62 million over the last four quarters. The company reported shareholder's funds of 6.18 million and total assets of 8.70 million as of Dec 24.

View full answer

What does CNS Pharmaceuticals, Inc. do?

22-Jun-2025

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company focused on developing anticancer drug candidates, particularly Berubicin for glioblastoma. It has a market cap of USD 4.53 million and reported a net profit loss of USD 4 million as of March 2025.

View full answer

Is CNS Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of May 1, 2025, CNS Pharmaceuticals, Inc. shows a mildly bearish trend overall, with mixed technical indicators and significant underperformance against the S&P 500, recording a year-to-date return of -87.79% compared to the S&P 500's 12.22%.

View full answer

Compare CNS Pharmaceuticals, Inc. with Similar Stocks

SeqLL, Inc.Bellerophon Therapeutics, Inc.Hoth Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.99

Return on Equity

-131.90%

Price to Book

0.15

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-65.72%

6 Months

-73.8%

1 Year

-94.62%

2 Years

-99.98%

3 Years

104.46%

4 Years

-100.0%

5 Years

-100.0%

CNS Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

21.04%

EBIT to Interest (avg)

-16.88

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.17

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.95%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.15

EV to EBIT

0.63

EV to EBITDA

0.63

EV to Capital Employed

-8.31

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-131.90%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.5%)

Foreign Institutions

Held by 5 Foreign Institutions (1.8%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 42.86% vs -24.44% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.30",
          "val2": "-5.60",
          "chgp": "41.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-5.60",
          "chgp": "42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.16% vs -23.53% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.90",
          "val2": "-18.90",
          "chgp": "21.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.90",
          "val2": "-18.90",
          "chgp": "21.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.30

-5.60

41.07%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-3.20

-5.60

42.86%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 42.86% vs -24.44% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.90

-18.90

21.16%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.90

-18.90

21.16%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 21.16% vs -23.53% in Dec 2023

All Annual Results

Company CV

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

CNS Pharmaceuticals Inc. is a preclinical stage pharmaceutical company. The Company is focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors. The Company is focused on developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity. It results in the inhibition of DNA replication and repair, and Ribonucleic acid (RNA) and protein synthesis.

Company Coordinates

Company Details

2100 West Loop S Ste 900 , HOUSTON TX : 77027-3522

Tel:

https://cnspharma.com/

Registrar Details